23-Oct-2024
No headlines found.
AbCellera to Present at Upcoming Investor Conferences in November 2024
Business Wire (Tue, 22-Oct 4:05 PM ET)
Business Wire (Fri, 4-Oct 9:00 AM ET)
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
Business Wire (Thu, 26-Sep 4:05 PM ET)
AbCellera to Present at Upcoming Investor Conferences in September
Business Wire (Thu, 29-Aug 4:05 PM ET)
AbCellera Reports Q2 2024 Business Results
Business Wire (Tue, 6-Aug 4:05 PM ET)
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
Business Wire (Wed, 31-Jul 9:00 AM ET)
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of October 23, 2024, ABCL stock price declined to $2.78 with 1,081,499 million shares trading.
ABCL has a beta of 1.22, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.08 to the broad based SPY ETF.
ABCL has a market cap of $819.17 million. This is considered a Small Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $7 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.01.
In the last 3 years, ABCL traded as high as $17.93 and as low as $2.34.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, IDNA, SPDW, GWX, LRNZ.
ABCL has underperformed the market in the last year with a return of -35.6%, while the SPY ETF gained +38.9%. In the last 3 month period, ABCL fell short of the market, returning -7.6%, while SPY returned +4.5%. However, in the most recent 2 weeks ABCL has outperformed the stock market by returning +8.2%, while SPY returned +0.8%.
ABCL support price is $2.76 and resistance is $2.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.